Bristol Myers, Exelixis announce Opdivo in combo with Cabometyx shows durable survival with over 3 years of follow-up in CheckMate -9ER trial in first-line advanced RCC

Press/Media

Period15 Feb 2023

Media coverage

1

Media coverage

  • TitleBristol Myers, Exelixis announce Opdivo in combo with Cabometyx shows durable survival with over 3 years of follow-up in CheckMate -9ER trial in first-line advanced RCC
    Media name/outletPharmaBiz
    Country/TerritoryIndia
    Date15/02/23
    PersonsMauricio Burotto